Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma
NCT00970996
Completed
The goal of this clinical research study is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given in combination with cisplatin, Temodar (temozolomide), interferon alfa-2b, and interleukin-2 (IL-2) to patients with metastatic melanoma. Primary Objective: * The primary objective of the Phase I is to determine the toxicity, safety and the maximum tolerated dose maximum tolerated dose of Abraxane in combination with Cisplatin, Temozolomide, interleukin-2 and interferon a2b in... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/31/2012
Locations: U.T. M.D. Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix
NCT00003377
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Paclitaxel and cisplatin may increase the effectiveness of radiation therapy by making the tumor cells more sensitive to the radiation. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel when given with r... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/27/2012
Locations: University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida +12 locations
Conditions: Cervical Cancer
Register for Updates
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
NCT00621361
Completed
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for whom EP would be a standard therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2012
Locations: Research Site, Sacramento, California +3 locations
Conditions: Lung Cancer
Register for Updates
Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT01015664
Terminated
This study will accrue in two "phases". During the first "phase" of the study, the optimal dose of temsirolimus in combination with cisplatin and cetuximab will be determined. It is expected that between 9-12 patients will be needed for this dose finding phase. Once the optimal dose has been determined, an additional 41 patients will be enrolled in the second "phase" of the study. The primary purpose of second phase of the study is to learn what effects, good and/or bad, temsirolimus in combinat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2012
Locations: Boston Baskin Caner Foundation, Memphis, Tennessee
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy
NCT00379665
Completed
This study is being conducted in order to determine if intratumoral chemotherapy will be helpful in the palliation of endobronchial tumors when used in conjunction with endobronchial brachytherapy.
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
12/10/2012
Locations: Cancer Treatment Centers of America ® Southwestern Regional Medical Center, Tulsa, Oklahoma
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Bryostatin 1 Plus Cisplatin in Treating Patients With Metastatic or Unresectable Cancer
NCT00003132
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of bryostatin 1 plus cisplatin in treating patients who have metastatic or unresectable cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2012
Locations: NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT00005051
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/08/2012
Locations: Albert Einstein Clinical Cancer Center, Bronx, New York +9 locations
Conditions: Ovarian Cancer
Register for Updates
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor
NCT00003211
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation therapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with topotecan, cyclophosphamide, cisplatin, and vincristine plus radiation therapy and peripheral stem cell transplant... Read More
Gender:
ALL
Ages:
Between 3 years and 20 years
Trial Updated:
11/06/2012
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee +3 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00682383
Completed
To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
10/29/2012
Locations: Mount Sinai Medical Center, Miami Beach, Florida
Conditions: Unresectable Locally Advanced NSCLC
Register for Updates
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
NCT01604863
Suspended
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2012
Locations: Not set, Scottsdale, Arizona +1 locations
Conditions: Cancer
Register for Updates
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
NCT00482014
Completed
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2012
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California +10 locations
Conditions: Non-Small-Cell Lung Cancer
Register for Updates
CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)
NCT00346801
Completed
Primary Objectives: * To determine the feasibility, activity, and toxicity of a novel regimen using a concurrent irinotecan (CPT-11)/cisplatin and celecoxib combination for patients with unresectable NSCLC. * To determine the maximal tolerance dose of celecoxib in patients with unresectable NSCLC treated with irinotecan/cisplatin and concurrent thoracic radiation therapy. * To correlate the COX-2 expression and other biomarkers with response to the treatment in the tumor from a pretreatment bio... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/19/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Register for Updates